simcyp pbpk simulator v21 (Certara L.P)
90
Structured Review
Certara L.P
simcyp pbpk simulator v21
Simcyp Pbpk Simulator V21, supplied by Certara L.P, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+simulator+v23/pmc11773107-133-6-10
Average 90 stars, based on 1 article reviews
Simcyp Pbpk Simulator V21, supplied by Certara L.P, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+simulator+v23/pmc11773107-133-6-10
Average 90 stars, based on 1 article reviews
simcyp pbpk simulator v21 - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Physiologically based pharmacokinetic modelling to predict potential drug–drug interactions of dersimelagon (MT‐7117)"
Article Title: Physiologically based pharmacokinetic modelling to predict potential drug–drug interactions of dersimelagon (MT‐7117)
Journal: British Journal of Clinical Pharmacology
doi: 10.1111/bcp.16271
Figure Legend Snippet: Key PBPK modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.
Techniques Used: In Vitro
Figure Legend Snippet: Input parameters of the physiologically based pharmacokinetic model for dersimelagon.
Techniques Used: Binding Assay, Software, Permeability, In Vitro, Inhibition
Related Articles
other:Article Title: Model-informed repurposing of eliglustat for treatment and prophylaxis of Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) in children. Article Snippet: PBPK simulations were conducted using the Article Title: Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates. Article Snippet: Development and refinement of PBPK models PBPK modeling and simulations were performed following a stepwise approach (Figure 1) using the Article Title: Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes Article Snippet: PBPK models were developed using the Article Title: Inhibition of Neural Crest Cell Migration by Strobilurin Fungicides and Other Mitochondrial Toxicants Article Snippet: A physiology-based kinetic (PBK) modeling was performed for picoxystrobin in the Software:Article Title: Drug-Drug Interaction Potential of Mavacamten with Midazolam: Combined Results from Clinical and Model-Based Studies. Article Snippet: .. Simulations Using a PBPK Model APBPKmodel was previously developed using Article Title: Heterotropic Allosteric Modulation of CYP3A4 In Vitro by Progesterone: Evidence for Improvement in Prediction of Time Dependent Inhibition for Macrolides. Article Snippet: 226 words) Predictions of drug-drug interactions resulting from time-dependent inhibition (TDI) of CYP3A4 have consistently overestimated or mis-predicted (i.e. false positives) the interaction that is observed in vivo.. Recent findings demonstrated that the presence of the allosteric modulator progesterone (PGS) in the in vitro assay could alter the in vitro kinetics of CYP3A4 TDI with inhibitors that interact with the heme moiety, such as metabolic-intermediate complex (MIC) forming inhibitors.. The impact of the presence of 100 μM PGS on the TDI of molecules in the class of macrolides typically associated with MIC formation was investigated. Article Title: Quantitative contributions of hepatic and renal organic cation transporters to the clinical pharmacokinetic cimetidine-metformin interaction Article Snippet: .. A PBPK model was developed to investigate the DDI between metformin and cimetidine using Clinical Proteomics:Article Title: Heterotropic Allosteric Modulation of CYP3A4 In Vitro by Progesterone: Evidence for Improvement in Prediction of Time Dependent Inhibition for Macrolides. Article Snippet: 226 words) Predictions of drug-drug interactions resulting from time-dependent inhibition (TDI) of CYP3A4 have consistently overestimated or mis-predicted (i.e. false positives) the interaction that is observed in vivo.. Recent findings demonstrated that the presence of the allosteric modulator progesterone (PGS) in the in vitro assay could alter the in vitro kinetics of CYP3A4 TDI with inhibitors that interact with the heme moiety, such as metabolic-intermediate complex (MIC) forming inhibitors.. The impact of the presence of 100 μM PGS on the TDI of molecules in the class of macrolides typically associated with MIC formation was investigated. |